Document Detail


Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers.
MedLine Citation:
PMID:  16398595     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. However, the perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which is necessary for prevention efforts to be successful. Chinese red yeast rice (CRYR) is a supplement containing lovastatin (monacolin K), eight other monacolins, pigments, tannins, and other phytochemicals. The authors previously reported on a double- blind placebo-controlled trial of CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study compared the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol. METHODS: Eleven (11) healthy volunteers were randomized to a crossover study taking 2400 mg CRYR or 20 mg of lovastatin. RESULTS: The Cmax and area under the curve (AUC) of lovastatin were 22.42 ng/mL, and 80.47 higher than CRYR (p = 0.001 and 0.002, respectively). The Cmax for lovastatin hydroxy-acid was 36.63 ng/mL higher than the Cmax of CRYR hydroxy-acid (p = 0.001). The AUC of lovastatin hydroxy-acid was 258.5 greater than that of CRYR (p = 0.001). CONCLUSIONS: The results suggested that the effect of CRYR on the cholesterol concentration might be caused by the additive and/or synergistic effects of monacolin K with other monacolins and substances in CRYR. It may lead to the ultimate development of a botanical supplement based on CRYR.
Authors:
Zhaoping Li; Navindra P Seeram; Rupo Lee; Gail Thames; Chayo Minutti; He-Jing Wang; David Heber
Related Documents :
11368995 - The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens.
11220455 - Aggressive treatment of dyslipidemia: a review of supporting evidence.
12467935 - The rationale for combination therapy.
19895945 - Novel targets that affect high-density lipoprotein metabolism: the next frontier.
21497615 - Effect of 2-hydroxyestradiol on binge intake in rats.
10223195 - A comparison of the effects of dietary cellulose and fermentable galacto-oligosaccharid...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Journal of alternative and complementary medicine (New York, N.Y.)     Volume:  11     ISSN:  1075-5535     ISO Abbreviation:  J Altern Complement Med     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2006-01-09     Completed Date:  2006-06-06     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9508124     Medline TA:  J Altern Complement Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1031-8     Citation Subset:  IM    
Affiliation:
Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA90095-1742, USA. zli@mednet.ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anticholesteremic Agents / administration & dosage,  blood,  pharmacokinetics*
Area Under Curve
Biological Products / administration & dosage,  blood,  pharmacokinetics*
Cholesterol / blood
Chromatography, High Pressure Liquid
Cross-Over Studies
Female
Humans
Lovastatin / administration & dosage,  blood,  pharmacokinetics*
Male
Middle Aged
Plasma / metabolism
Reference Values
Grant Support
ID/Acronym/Agency:
IP50 AT 000151-01/AT/NCCAM NIH HHS
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Biological Products; 0/red yeast rice; 57-88-5/Cholesterol; 75330-75-5/Lovastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Echinacea purpurea for prevention of upper respiratory tract infections in children.
Next Document:  Omega-3 fatty acids for the treatment of cancer cachexia: issues in designing clinical trials of die...